Approximately 70% of breast cancers present as ERα positive (+) and respond to anti-estrogen therapy such as tamoxifen, a commonly prescribed endocrine agent that exerts anti-cancer effect via competing with estrogen for binding to ERα2. This evidence concerns the gene ESR1 and breast carcinoma.